

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
25 August 2005 (25.08.2005)

PCT

(10) International Publication Number
WO 2005/077391 A1

(51) International Patent Classification⁷: **A61K 35/74**,
A61P 29/00

(21) International Application Number:
PCT/SE2005/000220

(22) International Filing Date: 17 February 2005 (17.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0400355-4 17 February 2004 (17.02.2004) SE

(71) Applicant (for all designated States except US): **SYNBI-
OTICS AB** [SE/SE]; Box 5003, S-105 46 Stockholm (SE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **BENGMARK, Stig**
[SE/SE]; Kustvägen 13, S-263 32 Höganäs (SE).

(74) Agent: **STRÖM & GULLIKSSON IPC AB**; P.O. Box
4188, S-203 13 Malmö (SE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: NEW SYNBIOTIC USE

(57) Abstract: The invention relates to the use of at least two lactic acid bacterial strains selected from the group comprising *Pe-
diococcus pentosaceus* 16:1 (LMG P-20608), *Leuconostoc mesenteroides* 23-77:1 (LMG P-20607), *Lactobacillus paracasei* subsp
paracasei F-19 (LMG P-17806), and *Lactobacillus plantarum* 2362 (LMG P-20606) for the manufacturing of a formulation for the
prevention or treatment of stress-induced inflammatory disorder.

WO 2005/077391 A1